Eliem Therapeutics (ELYM) Stock Chart & Stock Price History $1.19 -0.05 (-4.03%) As of 07/1/2025 Add Compare Share Share Chart Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock Eliem Therapeutics Stock Price Performance The Eliem Therapeutics (ELYM) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 82.65%, with a year-to-date return of -35.68%. In the past month, the stock has increased 0.85%, reflecting recent market activity. As of the latest close, Eliem Therapeutics traded at $1.19 with a market cap of $35.41 million and volume of 215,669 shares. Receive ELYM Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance-8.46%1 Month Performance+0.85%3 Month Performance-1.65%Year-To-Date Performance-35.68%1 Year Performance-82.65% ELYM Stock Chart for Thursday, July, 3, 2025 ELYM Chart by TradingView Eliem Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization07/02/2025$1.24$1.19-4.03%$1.25$1.19215,669 shs$35.41 million07/01/2025$1.18$1.24+5.08%$1.25$1.20186,214 shs$36.89 million06/30/2025$1.18$1.18$1.29$1.183.60 million shs$35.11 million06/27/2025$1.30$1.30$1.34$1.23220,937 shs$38.68 million06/26/2025$1.29$1.30+0.78%$1.34$1.23220,937 shs$38.68 million06/25/2025$1.20$1.29+7.50%$1.31$1.20417,602 shs$38.38 million06/24/2025$1.21$1.20-0.83%$1.25$1.17252,025 shs$35.70 million06/23/2025$1.21$1.21$1.25$1.18189,507 shs$36 million06/20/2025$1.23$1.23$1.29$1.16283,275 shs$36.60 million06/19/2025$1.20$1.23+2.50%$1.29$1.16283,275 shs$36.60 million Get the Latest News and Ratings for ELYM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 06/18/2025$1.27$1.20-5.51%$1.31$1.20190,182 shs$35.70 million06/17/2025$1.26$1.27+0.79%$1.31$1.21162,475 shs$37.79 million06/16/2025$1.26$1.26$1.30$1.21168,444 shs$37.49 million06/13/2025$1.26$1.28+1.59%$1.30$1.21135,718 shs$38.08 million06/12/2025$1.37$1.26-8.03%$1.37$1.26204,220 shs$37.49 million06/11/2025$1.34$1.37+2.24%$1.40$1.30160,710 shs$40.76 million06/10/2025$1.39$1.34-3.60%$1.45$1.31252,865 shs$39.87 million06/09/2025$1.39$1.39$1.47$1.271.01 million shs$41.36 million06/06/2025$1.29$1.24-3.88%$1.30$1.2271,754 shs$36.89 million06/05/2025$1.29$1.29$1.36$1.2878,540 shs$38.38 million06/04/2025$1.18$1.29+9.32%$1.30$1.18179,303 shs$38.38 million06/03/2025$1.18$1.18$1.23$1.16114,022 shs$35.11 million06/02/2025$1.18$1.18$1.23$1.17109,509 shs$35.11 million Related Companies Fate Therapeutics Stock Price Chart Kyverna Therapeutics Stock Price Chart Black Diamond Therapeutics Stock Price Chart Vaxart Stock Price Chart Lexeo Therapeutics Stock Price Chart Lyell Immunopharma Stock Price Chart BeyondSpring Stock Price Chart Neumora Therapeutics Stock Price Chart Nkarta Stock Price Chart FitLife Brands Stock Price Chart Receive ELYM Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:ELYM) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eliem Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.